

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/O3D47B1F7AAEN.html>

Date: September 2019

Pages: 52

Price: US\$ 2,000.00 (Single User License)

ID: O3D47B1F7AAEN

Abstracts

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide

covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).

The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Opioid-Induced Constipation (OIC) - Overview

Opioid-Induced Constipation (OIC) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opioid-Induced Constipation (OIC) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development

Bausch Health Companies Inc

Mallinckrodt Plc

Shionogi & Co Ltd

Opioid-Induced Constipation (OIC) - Drug Profiles

dolcanatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ibuprostone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naldemedine tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opioid-Induced Constipation (OIC) - Dormant Projects

Opioid-Induced Constipation (OIC) - Discontinued Products

Opioid-Induced Constipation (OIC) - Product Development Milestones

Featured News & Press Releases

Aug 28, 2019: BioDelivery Sciences announces presentation on Symproic at PAINWeek 2019 National Conference on Pain Management

Feb 22, 2019: Shionogi receives European Union Marketing Authorisation for Rizmoic (naldemedine) for the treatment of opioid-induced constipation in adults previously treated with a laxative

Dec 18, 2018: Shionogi receives positive opinion for Rizmoic in latest announcement from the Committee for Medicinal Products for Human Use (CHMP)

Dec 13, 2018: Rizmoic (naldemedine) received a positive opinion for the treatment of opioid-induced constipation

Sep 04, 2018: Shionogi announces upcoming presentations from Symproic (naldemedine) studies at PAINWeek 2018 Annual Conference

Jul 09, 2018: Shionogi Regains Full Rights to Symproic (naldemedine) in the US

Mar 06, 2018: Fifty-Two Week Safety Study on Symproic (naldemedine) for Opioid-induced Constipation (OIC) in Adults with Chronic Non-cancer Pain Published in PAIN

Oct 12, 2017: Shionogi and Purdue Pharma Announce U.S. Availability of Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

Sep 06, 2017: Shionogi and Purdue Pharma to Present Data from Naldemedine Studies at PAINWeek 2017 Annual Conference

Jun 07, 2017: Opioid-Induced Constipation therapeutic agent 'Symproic (naldemedine) Tablets 0.2mg' launched in Japan

Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan

Mar 24, 2017: EMA Accepts MAA Submission of Shionogi's Naldemedine for the Treatment of Opioid-Induced Constipation

Mar 23, 2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

Dec 19, 2016: Shionogi and Purdue Pharma Establish Alliance for Joint U.S. Commercialization of Naldemedine

Sep 07, 2016: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation

Appendix

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Opioid-Induced Constipation (OIC) - Pipeline by Bausch Health Companies Inc, H2 2019

Opioid-Induced Constipation (OIC) - Pipeline by Mallinckrodt Plc, H2 2019

Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, H2 2019

Opioid-Induced Constipation (OIC) - Dormant Projects, H2 2019

Opioid-Induced Constipation (OIC) - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Bausch Health Companies Inc

Mallinckrodt Plc

Shionogi & Co Ltd

I would like to order

Product name: Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/O3D47B1F7AAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O3D47B1F7AAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970